Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inga Nehlmeier

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
The Lancet. Infectious Diseases|November 10, 2024
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XECPrerna Arora, Christine Happle, Amy Kempf, et al.
Journal of Virology|October 7, 2016
The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific AntibodiesConstantin Brinkmann, Inga Nehlmeier, Kerstin Walendy-Gnirß, et al.
Plos One|June 22, 2017
Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2Lennart Michel Reinke, Martin Spiegel, Teresa Plegge, et al.
Cellular & Molecular Immunology|January 5, 2022
No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2Prerna Arora, Amy Kempf, Inga Nehlmeier, et al.
The Lancet. Infectious Diseases|March 1, 2025
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1Lu Zhang, Amy Kempf, Inga Nehlmeier, et al.
ACS Applied Materials & Interfaces|April 6, 2026
Probing Glycan-Gold Nanoparticle Architectures: Glycan Type, Density, and Linker Length, Governing Multivalent Lectin Binding and Viral InhibitionMaisie Holbrow-Wilshaw, Darshita Budhadev, Amy Madeleine Kempf, et al.
The Lancet. Infectious Diseases|July 1, 2022
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5Prerna Arora, Amy Kempf, Inga Nehlmeier, et al.
Kidney Medicine|September 8, 2025
Humoral Immune Responses in Dialysis Patients After mRNA Omicron JN.1 VaccinationMetodi V Stankov, Markus Hoffmann, Christine Happle, et al.
The Lancet. Infectious Diseases|November 24, 2025
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisationChristine Happle, Markus Hoffmann, Metodi V Stankov, et al.
JACS Au|August 30, 2024
Polyvalent Glycomimetic-Gold Nanoparticles Revealing Critical Roles of Glycan Display on Multivalent Lectin-Glycan Interaction Biophysics and Antiviral PropertiesXinyu Ning, Darshita Budhadev, Sara Pollastri, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
The Lancet. Infectious Diseases|November 10, 2024
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XECPrerna Arora, Christine Happle, Amy Kempf, et al.
Journal of Virology|October 7, 2016
The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific AntibodiesConstantin Brinkmann, Inga Nehlmeier, Kerstin Walendy-Gnirß, et al.
Plos One|June 22, 2017
Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2Lennart Michel Reinke, Martin Spiegel, Teresa Plegge, et al.
Cellular & Molecular Immunology|January 5, 2022
No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2Prerna Arora, Amy Kempf, Inga Nehlmeier, et al.
The Lancet. Infectious Diseases|March 1, 2025
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1Lu Zhang, Amy Kempf, Inga Nehlmeier, et al.
ACS Applied Materials & Interfaces|April 6, 2026
Probing Glycan-Gold Nanoparticle Architectures: Glycan Type, Density, and Linker Length, Governing Multivalent Lectin Binding and Viral InhibitionMaisie Holbrow-Wilshaw, Darshita Budhadev, Amy Madeleine Kempf, et al.
The Lancet. Infectious Diseases|July 1, 2022
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5Prerna Arora, Amy Kempf, Inga Nehlmeier, et al.
Kidney Medicine|September 8, 2025
Humoral Immune Responses in Dialysis Patients After mRNA Omicron JN.1 VaccinationMetodi V Stankov, Markus Hoffmann, Christine Happle, et al.
The Lancet. Infectious Diseases|November 24, 2025
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisationChristine Happle, Markus Hoffmann, Metodi V Stankov, et al.
JACS Au|August 30, 2024
Polyvalent Glycomimetic-Gold Nanoparticles Revealing Critical Roles of Glycan Display on Multivalent Lectin-Glycan Interaction Biophysics and Antiviral PropertiesXinyu Ning, Darshita Budhadev, Sara Pollastri, et al.
Pageof 8